Wire · opportunities
Eyconis Initiates First-in-Human Clinical Trial of EYC-0305 in Treatment-Naïve Wet AMD
◆ Sectors
◆ Geography
◆ Source
◆ Verified
Fusion42 · 20 August 2026 · Fusion42 review
Eyconis has initiated the OVERTURE phase 1b/2a clinical trial to test EYC-0305, a new long-acting anti-VEGF therapy for treatment-naïve wet AMD patients, aiming to extend dosing intervals to six months without surgery, implants, or devices.
This Wire brief sits within Fusion42's coverage of Medtech.
◆ ◆ The Wire takeaway
You can now plan for a new treatment option that could halve wet AMD patient visits with longer dosing periods, shifting care models and reducing clinic load. Developers of retinal therapies must prepare for competition from longer-acting injectable drugs that avoid surgery and implants.
◆ Coverage
1 source · 20 Aug 2026
◆ Related on Wire
◆ Topics